Cargando…

A multicenter observational safety study in Swedish children and adolescents using insulin detemir for the treatment of type 1 diabetes

This 26-wk observational study in children and adolescents with type 1 diabetes (T1D) in Sweden investigated the safety and efficacy of insulin detemir (IDet) in newly diagnosed (ND) patients and those with established diabetes (ED) switching to IDet. A total of 159 patients initiated IDet as part o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlsson, Annelie, Forsander, Gun, Ludvigsson, Johnny, Larsen, Sara, Örtqvist, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons A/S 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810710/ https://www.ncbi.nlm.nih.gov/pubmed/23448369 http://dx.doi.org/10.1111/pedi.12019

Ejemplares similares

Month of birth and the risk of developing type 1 diabetes among children in the Swedish national Better Diabetes Diagnosis Study
por: Hedlund, Emma, et al.
Publicado: (2022)

Absence of Islet Autoantibodies and Modestly Raised Glucose Values at Diabetes Diagnosis Should Lead to Testing for MODY: Lessons From a 5-Year Pediatric Swedish National Cohort Study
por: Carlsson, Annelie, et al.
Publicado: (2020)

Zinc Transporter 8 Autoantibodies and Their Association With SLC30A8 and HLA-DQ Genes Differ Between Immigrant and Swedish Patients With Newly Diagnosed Type 1 Diabetes in the Better Diabetes Diagnosis Study
por: Delli, Ahmed J., et al.
Publicado: (2012)

Celiac disease can be predicted by high levels of tissue transglutaminase antibodies in children and adolescents with type 1 diabetes
por: Cerqueiro Bybrant, Mara, et al.
Publicado: (2020)

Insulin pump therapy is associated with higher rates of mild diabetic ketoacidosis compared to injection therapy: A 2‐year Swedish national survey of children and adolescents with type 1 diabetes
por: Wersäll, Johan H., et al.
Publicado: (2022)

High Plasma Levels of Islet Amyloid Polypeptide in Young with New-Onset of Type 1 Diabetes Mellitus
por: Paulsson, Johan F., et al.
Publicado: (2014)

Next-Generation Sequencing Reveals That HLA-DRB3, -DRB4, and -DRB5 May Be Associated With Islet Autoantibodies and Risk for Childhood Type 1 Diabetes
por: Zhao, Lue Ping, et al.
Publicado: (2016)

Two Insulin Gene Single Nucleotide Polymorphisms Associated with Type 1 Diabetes Risk in the Finnish and Swedish Populations
por: Laine, Antti-Pekka, et al.
Publicado: (2007)

Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy
por: Dündar, Bumin Nuri, et al.
Publicado: (2009)

Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2–16 Years
por: Thalange, Nandu, et al.
Publicado: (2016)

Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes
por: Philis-Tsimikas, Athena
Publicado: (2008)

Clinical safety of insulin detemir in patients with Type 2 diabetes in the Gulf countries: The multicenter, noninterventional, open-label LevSafe study
por: El Shiekh, Abdel Rahman, et al.
Publicado: (2016)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK
por: Thalange, Nandu, et al.
Publicado: (2019)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
por: Le Floch, Jean-Pierre
Publicado: (2010)

Insulin Detemir in the Treatment of Type 1 and Type 2 Diabetes
por: Philips, Jean-Christophe, et al.
Publicado: (2006)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander, Priscilla A
Publicado: (2012)

The role of insulin detemir in overweight type 2 diabetes management
por: Demssie, Yared N, et al.
Publicado: (2009)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Safety and Effectiveness of Insulin Detemir in Different Age-Groups in the A(1)chieve Study
por: Malek, Rachid, et al.
Publicado: (2013)

Residual beta cell function at diagnosis of type 1 diabetes in children and adolescents varies with gender and season
por: Samuelsson, U, et al.
Publicado: (2013)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson, Scott E
Publicado: (2011)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Cerebrocortical Beta Activity in Overweight Humans Responds to Insulin Detemir
por: Tschritter, Otto, et al.
Publicado: (2007)

Insulin Detemir in Pregnancy: A Small but Significant Step Forward?
por: McElduff, Aidan
Publicado: (2012)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
por: Pscherer, Stefan, et al.
Publicado: (2010)

Inequalities in cardiovascular risks among Swedish adolescents (ABIS): a prospective cohort study
por: Andersson White, Pär, et al.
Publicado: (2020)

O01 - Validation of asthma and eczema in population-based Swedish health registers
por: Örtqvist, Anne K, et al.
Publicado: (2014)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)
por: Wheeler, Mark D., et al.
Publicado: (2018)

Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study
por: ji, Jing, et al.
Publicado: (2020)

Impact of Fat Intake on Blood Glucose Control and Cardiovascular Risk Factors in Children and Adolescents with Type 1 Diabetes
por: Garonzi, Chiara, et al.
Publicado: (2021)

Sustained Treatment with Insulin Detemir in Mice Alters Brain Activity and Locomotion
por: Sartorius, Tina, et al.
Publicado: (2016)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
por: Peterson, Gregory E
Publicado: (2009)

Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes
por: Mathiesen, Elisabeth R., et al.
Publicado: (2012)

HTR1A a Novel Type 1 Diabetes Susceptibility Gene on Chromosome 5p13-q13
por: Asad, Samina, et al.
Publicado: (2012)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010)

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
por: Asias, Bernadette D., et al.
Publicado: (2015)

Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial
por: Ludvigsson, Johnny, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v36shfsoq947391cve5abk6p1s